Ge Long Hui·2025-09-22 11:39Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has announced the initiation of Phase II clinical trials for its pediatric Xiaochaihu granules, which are primarily used for treating pediatric gastrointestinal colds [1] Group 1: Clinical Trial Information - The pediatric Xiaochaihu granules have recently been registered for Phase II clinical trials on the National Medical Products Administration's platform [1] - Guanghua Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration in May 2023 [1] - The project has incurred approximately RMB 18.59 million in research and development expenses to date [1] Group 2: Market Context - There are currently no similar products for pediatric Xiaochaihu granules available in the domestic or international markets [1] - No sales data for comparable products is available domestically or internationally [1]